logo
  

Kamada Reaches Deal With Israeli Ministry To Supply Plasma-derived IgG Product For COVID-19

Kamada Ltd. (KMDA) has signed an agreement with the Israeli Ministry of Health to supply its anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin (IgG) product for the treatment of COVID-19 patients in Israel. The company expects initial supply to generate approximately $3.4 million in revenue for Kamada during the first quarter of 2021.

Treatment with Kamada's investigational IgG product will be regulated by the Israeli Ministry of Health. The phase 1/2 trial in Israel is being conducted as part of Kamada's global collaboration with Kedrion Biopharma, for the development, manufacturing, and distribution of a plasma-derived IgG product as a potential treatment for COVID-19.

Amir London, CEO, said: "We are encouraged by the interim results of the ongoing Phase 1/2 clinical trial in Israel, in which our product demonstrated a favorable safety profile and showed symptoms improvement in hospitalized, non-ventilated COVID-19 patients with pneumonia, and we will continue to ramp up the production and supply of the product during the next few months."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT